Ranibizumab 2.3 mg Injection

Ranibizumab 2.3 mg Injection – Anti-VEGF Treatment for Retinal Eye Disorders

Ranibizumab 2.3 mg Injection contains Ranibizumab 2.3 mg in 0.23 ml, equivalent to a concentration of 10 mg/ml. It is a prescription ophthalmic medicine supplied in a single-use vial for administration directly into the eye. Ranibizumab is an anti-VEGF medicine that blocks vascular endothelial growth factor A. This protein contributes to the growth and leakage of abnormal blood vessels in the retina, which may cause retinal swelling, bleeding, and loss of vision. Ranibizumab Injection must be administered only by a qualified ophthalmologist experienced in intravitreal injections. The treatment dose, injection frequency, and duration depend on the diagnosed retinal condition, eye examinations, retinal imaging results, and response to treatment.

Key Features

• Contains Ranibizumab: An anti-VEGF monoclonal antibody fragment.
• Supports Retinal Treatment: Helps control abnormal blood-vessel growth and fluid leakage within the retina.
• Single-Use Vial: Contains 2.3 mg of ranibizumab in 0.23 ml solution.
• Intravitreal Administration: Injected directly into the vitreous cavity of the eye.
• Specialist-Only Treatment: Must be administered by a trained ophthalmologist.
• Cold-Chain Medicine: Requires refrigerated storage and protection from light.

Active Ingredient

• Ranibizumab 2.3 mg/0.23 ml: An anti-VEGF medicine that helps reduce abnormal retinal blood-vessel growth and vascular leakage.

Uses

• Neovascular or wet age-related macular degeneration.
• Diabetic macular edema.
• Macular edema following retinal vein occlusion.
• Diabetic retinopathy in eligible patients.
• Visual impairment caused by choroidal neovascularization.
• Other retinal conditions can be specifically diagnosed and treated by an ophthalmologist.

How It Is Administered

• Ranibizumab must be administered only by a qualified ophthalmologist.
• It is given as an intravitreal injection directly into the affected eye.
• It must not be self-administered or injected into a vein, muscle, or under the skin.
• The ophthalmologist will determine the exact dose required for each injection.
• The 2.3 mg stated on the vial represents the total vial content and not necessarily the amount administered.
• The vial is intended for single use only, and any unused solution must be discarded.
• Strict sterile and aseptic techniques must be followed during preparation and administration.

Warning

• Serious Eye Infection: Intravitreal injections may cause endophthalmitis, a potentially sight-threatening infection inside the eye.
• Retinal Complications: Retinal tear, retinal detachment, intraocular inflammation, bleeding, or traumatic cataract may occur.
• Increased Eye Pressure: Intraocular pressure may increase temporarily after the injection.

Possible Side Effects

• Eye pain, irritation, itching, or discomfort.
• Eye redness or bleeding on the surface of the eye.
• Temporary blurred vision or visual disturbances.
• Floaters or a foreign-body sensation in the eye.
• Dry eye or increased tearing.
• Increased pressure inside the eye.
• Headache.
• Allergic reactions such as rash, itching, or swelling.

Storage

• Store in a refrigerator between 2°C and 8°C.
• Do not freeze.
• Keep the vial in its original carton to protect it from light.
• Do not shake the vial.
• Do not use if the solution appears cloudy, discoloured, or contains visible particles.
• Do not use if the vial or packaging is opened, damaged, or tampered with.
• The vial is intended for single use only.
• Keep out of reach of children and unauthorized individuals.

Legal Disclaimer: Ranibizumab 2.3 mg Injection is a prescription ophthalmic biological medicine intended exclusively for intravitreal administration by a qualified ophthalmologist. It may cause serious eye-related or systemic adverse reactions. This information is provided for educational purposes only and should not replace professional medical advice, diagnosis, treatment, or the official instructions supplied with the medicine.